Please Wait.....
Report
Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2023-2031
Market Report I 2023-04-28 I 160 Pages I EMR Inc.
Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2023-2031
Global Rheumatoid Arthritis Therapeutics Market Outlook
The value of the global rheumatoid therapeutics market was USD 28.21 billion in 2022, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2023-2031 to reach value of USD 42.28 billion by 2031.
Rheumatoid Arthritis Therapeutics: Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints. It occurs when the immune system mistakenly attacks the body's own tissues, leading to inflammation and joint damage. RA can cause pain, swelling, stiffness, and loss of function in the joints, as well as fatigue and other systemic symptoms. It is estimated that around 1% of the world's population is affected by RA, with women being more likely to develop the disease than men.
There is currently no cure for RA, but there are several types of medications that can help manage the symptoms and slow the progression of the disease. These include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. Treatment is typically tailored to the individual patient and may involve a combination of medications, as well as physical therapy and other supportive measures. Ongoing research is focused on developing more effective treatments for RA, as well as gaining a better understanding of the underlying mechanisms of the disease.
Rheumatoid Arthritis Therapeutics Application and Uses
Rheumatoid arthritis (RA) therapeutics are used to treat rheumatoid arthritis, which is a chronic autoimmune disorder that causes inflammation in the joints, leading to pain, stiffness, and swelling. The application and uses of RA therapeutics include:
- Reducing inflammation: The main objective of RA therapeutics is to reduce inflammation in the joints, which helps alleviate pain and stiffness. This is achieved through the use of disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents.
- Slowing down joint damage: RA therapeutics also aim to slow down the progression of joint damage by preventing the immune system from attacking the joints. DMARDs and biologic agents are effective in achieving this goal.
- Relieving pain: Pain relief is an important aspect of RA therapeutics. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are commonly used to relieve pain and inflammation.
- Improving physical function: RA can limit physical function due to joint pain and stiffness. Physical therapy and exercise can help improve physical function and reduce pain
- Preventing complications: RA therapeutics can also help prevent complications such as anaemia, osteoporosis, and cardiovascular disease, which can occur as a result of the disease or its treatment.
Overall, RA therapeutics aim to improve the quality of life for individuals with rheumatoid arthritis by reducing pain, inflammation, and joint damage, and improving physical function.
Global Rheumatoid Arthritis Therapeutics Market Segmentations
Market Breakup by Product Type
- Biologics
- Non-Biologics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
- Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
- Others
Market Breakup by Sales Type
- Prescription
- Over The Counter (OTC)
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online
Market Breakup by End User
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Global Rheumatoid Arthritis Therapeutics Market Scenario
Rheumatoid arthritis is a chronic autoimmune disorder that affects the joints and can lead to joint deformity, loss of function, and disability. The increasing prevalence of rheumatoid arthritis is a key driver of the market, along with the rising aging population and the growing awareness about the condition.
The market is also being driven by the increasing availability of advanced biologic therapies and the development of innovative treatment approaches. However, the high cost of these therapies and the availability of biosimilars could pose a challenge to market growth
Geographically, North America is expected to dominate the market due to the high prevalence of rheumatoid arthritis in the region, as well as the presence of key market players. Europe is also expected to witness significant growth due to the increasing demand for advanced biologic therapies.
Key Players in the Global Rheumatoid Arthritis Therapeutics Market
The report gives an in-depth analysis of the key players involved in the global rheumatoid arthritis therapeutics market. The companies included in the market are as follows:
- Pfizer Inc.
- Amgen Inc.?
- Bristol-Myers Squibb Company?
- F. Hoffmann-La Roche Ltd
- UCB S.A.
- Gilead Sciences, Inc.
- Boehringer Ingelheim GmbH
- Novartis International AG
- Regeneron Pharmaceuticals, Inc.
- AbbVie.
- Eli Lilly and Company
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Rheumatoid Arthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Rheumatoid Arthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Rheumatoid Arthritis Epidemiology (2016-2031)
5.3 Europe Rheumatoid Arthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Rheumatoid Arthritis Epidemiology (2016-2031)
5.5 Latin America Rheumatoid Arthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Rheumatoid Arthritis Epidemiology (2016-2031)
6 Global Rheumatoid Arthritis Therapeutics Market Overview
6.1 Global Rheumatoid Arthritis Therapeutics Market Historical Value (2016-2022)
6.2 Global Rheumatoid Arthritis Therapeutics Market Forecast Value (2023-2031)
7 Global Rheumatoid Arthritis Therapeutics Market Landscape
7.1 Rheumatoid Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Rheumatoid Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Rheumatoid Arthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Rheumatoid Arthritis Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Rheumatoid Arthritis Therapeutics Market Segmentation
11.1 Global Rheumatoid Arthritis Therapeutics Market by Product Type
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Non-Biologics
11.1.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.1.3.2 Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
11.1.3.3 Others
11.2 Global Rheumatoid Arthritis Therapeutics Market by Sales Type
11.2.1 Market Overview
11.2.2 Prescription
11.2.3 Over The Counter (OTC)
11.2.4 Others
11.3 Global Rheumatoid Arthritis Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Global Rheumatoid Arthritis Therapeutics Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online
11.5 Global Rheumatoid Arthritis Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals & Clinics
11.5.3 Research and Academic Laboratories
11.5.4 Others
11.6 Global Rheumatoid Arthritis Therapeutics Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Rheumatoid Arthritis Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Rheumatoid Arthritis Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Rheumatoid Arthritis Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Rheumatoid Arthritis Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Rheumatoid Arthritis Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Amgen Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bristol-Myers Squibb Company
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 F. Hoffmann-La Roche Ltd
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 UCB S.A.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Gilead Sciences, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Boehringer Ingelheim GmbH
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Novartis International AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Regeneron Pharmaceuticals, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 AbbVie.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Rheumatoid Arthritis Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security